Management of Systemic Lymphadenopathy in HIV Patients

Initial Clinical Assessment

The Centers for Disease Control and Prevention recommends distinguishing between benign persistent generalized lymphadenopathy (PGL) and pathologic lymphadenopathy, as localized lymphadenopathy, hepatomegaly, or splenomegaly may indicate infection or malignancy and requires further evaluation 1
The World Health Organization suggests assessing for constitutional symptoms (fever, night sweats, weight loss) which suggest opportunistic infection or malignancy 2, 3
The American College of Physicians recommends examining for skin lesions, oral candidiasis, or hairy leukoplakia which indicate advanced disease 1

The National Institutes of Health states that CD4 count determines the differential diagnosis and urgency of workup, with CD4 >500 cells/μL usually indicating no clinical immunosuppression and reactive lymphadenopathy most likely 2, 3, 4
The Centers for Disease Control and Prevention recommends that patients with CD4 200-500 cells/μL have an increased risk of HIV-related symptoms, and tuberculosis becomes more common 2, 3
The World Health Organization suggests that patients with CD4 <200 cells/μL are at high risk for opportunistic infections and lymphomas, and requires comprehensive evaluation in specialty setting 2, 3, 4

The American College of Physicians recommends that all HIV patients with significant lymphadenopathy require CD4+ T-lymphocyte count, HIV viral load, complete blood count, platelet count, syphilis serology, and tuberculin skin test 2, 3, 4, 5
The Infectious Diseases Society of America states that PPD ≥5 mm induration is considered positive in HIV patients and requires TB evaluation 2

The National Comprehensive Cancer Network recommends contrast-enhanced CT of chest, abdomen, and pelvis for initial staging 6
The Journal of the National Comprehensive Cancer Network suggests that FDG-PET/CT is more sensitive for extranodal disease but has higher false-positive rates in HIV due to opportunistic infections and immune deficiency-related lymphoid hyperplasia 7, 8, 6

The American College of Physicians recommends that no specific treatment is required for benign persistent generalized lymphadenopathy, but initiation or optimization of antiretroviral therapy to achieve viral suppression is necessary 1, 6
The National Institutes of Health states that for tuberculosis, standard anti-tuberculous therapy should be started immediately when diagnosed, and ART should be continued throughout TB treatment 6
The National Comprehensive Cancer Network recommends that for HIV-associated lymphomas, initiation or optimization of ART immediately and continuation during chemotherapy is necessary, and full-dose intensive chemotherapy with rituximab for CD20-positive disease should be used 6
The Annals of Oncology suggests that for Hodgkin lymphoma, ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is preferred due to lower toxicity 10, 11, 6

The Centers for Disease Control and Prevention recommends PCP prophylaxis strongly for CD4 <200 cells/μL or during chemotherapy 6
The Infectious Diseases Society of America suggests antiviral prophylaxis (acyclovir/valacyclovir) for CD4 <200 cells/μL, and consideration of antifungal prophylaxis (fluconazole) for CD4 <100 cells/μL 6